C225 and PDT combination therapy for ovarian cancer: the play's the thing.
Cengel
Keith A
KA
Hahn
Stephen M
SM
Glatstein
Eli
E
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology; D002277:Carcinoma / Q000188:drug therapy / Q000276:immunology / Q000556:secondary / Q000628:therapy*; D000068818:Cetuximab; D004357:Drug Synergism; D066246:ErbB Receptors / Q000187:drug effects* / Q000276:immunology; D005260:Female; D006414:Hematoporphyrin Photoradiation / Q000379:methods; D007167:Immunotherapy / Q000379:methods; D007274:Injections, Intraperitoneal; D028022:Low-Level Light Therapy / Q000379:methods; D051379:Mice; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000556:secondary / Q000628:therapy*; D017319:Photosensitizing Agents / Q000494:pharmacology; D011166:Porphyrins / Q000494:pharmacology*; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D017319:Photosensitizing Agents; D011166:Porphyrins; C504224:benzoporphyrin D; D066246:ErbB Receptors; D000068818:Cetuximab